Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Corylus americana pollen is a non-standardized allergenic extract derived from the pollen of the American hazelnut plant. It is marketed by Greer Laboratories, Inc. under the brand name "American Hazelnut Pollen". This product is indicated for both the diagnosis (via skin testing) and treatment (via immunotherapy) of individuals with immediate hypersensitivity allergies to this specific pollen. The extract is administered through intradermal, percutaneous, or subcutaneous routes. Its mechanism of action involves modulating the immune system's allergic response pathway to induce tolerance, which includes effects like increased IgG production and cell-mediated immunity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Corylus americana pollen.